U.S. Markets open in 25 mins.

Cempra, Inc. (CEMP)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
4.40+0.05 (+1.15%)
At close: 4:00PM EDT
People also watch
  • I'm telling you guys. The Weekly Parabolic SAR indicator doesn't mess around. We are in a likely a 6 month uptrend. We are still going to have our down days, but the overall trend is up for next 6 months (unless China invades USA or something crazy happens). And with this whole ML thing wrapping up, we could wake up one day to some significant news that makes the longs much happier than the shorts. Good luck longs.
  • does this bod and management have a plan or any angle with which to deal with the FDA. or are they wishing and a hoping approval for soli is going to fall from the sky!
  • [!] Option traders check out CreditSpreads.io, free live feed of mathematically profitable option credit spreads for the next month, sometimes including spreads for CEMP! High-probability option credit spreads deliver a solution to invest with specified risk and the maximum profit received right away. CreditSpreads.io targets exclusively the option spreads which meet its strict criteria for risk and profit, and contributes to continued profitability by warning you of any approaching situations which may affect the trade. http://www.creditspreads.io

    Sustainable, high probability, defined risk stock option trading opportunities.
  • they got nothing to buy for a buy out. save it pumpers.
  • If anyone believes these idiots led by super incompetent Zaccardelli can entice another company into buying Cempra just doesn't understand the extent of the incompetence that exists. MS is loving taking their cash due to their stupidity.

    Buyout? No F-in chance with these idiots at the controls!
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets


    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.


    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

    The short interest dropped from 5,431,967 shares to 4,850,555 shares on 6/30/2017.
  • Oh Oh Jeff Was Exposed...



  • Monster Microcaps Alert to CEMP shareholders. Clean Energy Technologies Moving broke out 4 weeks ago and is beginning to move again - CETY - price today $.02. Price target $.20 by year end. Clean Energy Technologies. CETY recently announced expansion with their Europe Sales and Service Center for Europe new sales and to serve 65 existing customers with CETY’s General Electric clean energy Heat Recovery Systems and just announced they have already sold the first of SEVERAL HUNDRED units to come over next 24 months.

    Each CETY Heat Recovery System sells for $300,000 and market demand is several BILLION DOLLARS.

    CETY purchased Heat Recovery Systems Division from General Electric and products are now very attractive to huge unmet markets and can achieve over $250 million in sales within the next 2 years. Demand for conversion of wasted heat to electrical energy in big applications is VERY LARGE AND UNMET.


    Clean Energy Technologies, Inc. Secures New Order for Waste Biomass Application in Europe
    COSTA MESA, Calif., July 12, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (CETY) announced today that its subsidiary Heat Recovery Solutions has secured a new Clean CycleTM generator order for a Waste Biomass application in Europe. Growing d
  • Are We Halted...


  • buyout today...
  • Big push coming next week. Momentum is your friend ... and now it's to the upside. Good luck longs!
  • Short Interest Is At All Time Lows...

    Will Not Belong Until Their Trapped...


  • The Sooner the Better for the Executives... Look at 8k... $CEMP Buy-Out...



  • Last Chance to Buy on the Cheap Side...

    Buy-Out coming soon...


  • Oh my gawd. Look at the buy out! It's yuge!!!!
  • Someone Just Took Out Stops... Buy-Out Coming...


  • Buy-Out... Do not do it on a Holiday week... Monday I Would Do It...

    So buy all the cheap shares you can...



  • Green Day Coming...


  • Why? Not One Lawsuit....Two Words( BUY-OUT )...

    You people can not be that dumb...

    Or can you?

    Back up the truck, before it is to late...